American journal of respiratory and critical care medicine
-
Am. J. Respir. Crit. Care Med. · Apr 2013
Multicenter Study Clinical TrialPrognostic value of bronchiectasis in patients with moderate-to-severe chronic obstructive pulmonary disease.
The prevalence of bronchiectasis is high in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) and it has been associated with exacerbations and bacterial colonization. These have demonstrated some degree of prognostic value in patients with COPD but no information about the relationship between bronchiectasis and mortality in patients with COPD is currently available. ⋯ Bronchiectasis was associated with an independent increased risk of all-cause mortality in patients with moderate-to-severe COPD.
-
Am. J. Respir. Crit. Care Med. · Apr 2013
Randomized Controlled Trial Multicenter StudyExploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study.
For many patients with asthma, allergic airway inflammation is primarily a Th2-weighted process; however, heterogeneity in patterns of inflammation suggests phenotypic distinctions exist that influence disease presentation and treatment effects. ⋯ The difference in exacerbation frequency between omalizumab and placebo was greatest in the three high-biomarker subgroups, probably associated with the greater risk for exacerbations in high subgroups. Additional studies are required to explore the value of these biomarkers in clinical practice. Clinical trial registered with www.clinicaltrials.gov (NCT00314574).